![Three-year Follow up of GMCSF/bi-shRNAfurin DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma: Molecular Therapy Three-year Follow up of GMCSF/bi-shRNAfurin DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma: Molecular Therapy](https://www.cell.com/cms/attachment/f15f10ba-24ab-43c4-94b1-06ab90bec4ed/gr1_lrg.jpg)
Three-year Follow up of GMCSF/bi-shRNAfurin DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma: Molecular Therapy
![Emerging trends in immunotherapy for pediatric sarcomas | Journal of Hematology & Oncology | Full Text Emerging trends in immunotherapy for pediatric sarcomas | Journal of Hematology & Oncology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13045-019-0756-z/MediaObjects/13045_2019_756_Fig1_HTML.png)
Emerging trends in immunotherapy for pediatric sarcomas | Journal of Hematology & Oncology | Full Text
![Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial - The Lancet Oncology Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/0ae1a419-8c04-4e6e-8a98-2b83b3eaa1d8/gr1.gif)
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial - The Lancet Oncology
![Cancers | Free Full-Text | Ewing Sarcoma Meets Epigenetics, Immunology and Nanomedicine: Moving Forward into Novel Therapeutic Strategies Cancers | Free Full-Text | Ewing Sarcoma Meets Epigenetics, Immunology and Nanomedicine: Moving Forward into Novel Therapeutic Strategies](https://www.mdpi.com/cancers/cancers-14-05473/article_deploy/html/images/cancers-14-05473-g001.png)
Cancers | Free Full-Text | Ewing Sarcoma Meets Epigenetics, Immunology and Nanomedicine: Moving Forward into Novel Therapeutic Strategies
![Frontiers | Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma Frontiers | Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma](https://www.frontiersin.org/files/Articles/454940/fonc-09-00537-HTML/image_m/fonc-09-00537-g001.jpg)
Frontiers | Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma
![3D Tissue-Engineered Tumor Model for Ewing's Sarcoma That Incorporates Bone-like ECM and Mineralization | ACS Biomaterials Science & Engineering 3D Tissue-Engineered Tumor Model for Ewing's Sarcoma That Incorporates Bone-like ECM and Mineralization | ACS Biomaterials Science & Engineering](https://pubs.acs.org/cms/10.1021/acsbiomaterials.9b01068/asset/images/large/ab9b01068_0007.jpeg)
3D Tissue-Engineered Tumor Model for Ewing's Sarcoma That Incorporates Bone-like ECM and Mineralization | ACS Biomaterials Science & Engineering
![Frontiers | The importance of fusion protein activity in Ewing sarcoma and the cell intrinsic and extrinsic factors that regulate it: A review Frontiers | The importance of fusion protein activity in Ewing sarcoma and the cell intrinsic and extrinsic factors that regulate it: A review](https://www.frontiersin.org/files/Articles/1044707/fonc-12-1044707-HTML/image_m/fonc-12-1044707-g001.jpg)
Frontiers | The importance of fusion protein activity in Ewing sarcoma and the cell intrinsic and extrinsic factors that regulate it: A review
![Immunotherapy for sarcomas: new frontiers and unveiled opportunities | Journal for ImmunoTherapy of Cancer Immunotherapy for sarcomas: new frontiers and unveiled opportunities | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/9/2/e001580/F1.large.jpg)